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A B S T R A C TObjective: Complementary and alternative medicine (CAM) has
gained increasing popularity over the last several decades interna-
tionally, leading to an increasing interest from decision makers and
researchers as to how to assess the effectiveness of CAM. The
attempts, however, have been unsatisfactory. The most important
reason is a lack of attention to the theoretical characteristics of CAM,
which are completely different from those of allopathic medicine or
biomedicine. This study attempted to survey expert Traditional
Chinese Medicine (TCM) practitioners in China to elucidate critical
issues when assessing the effectiveness of TCM. Methods: A ques-
tionnaire (with 20 close-ended and 2 open-ended questions) about the
influencing factors of measuring the cost and effectiveness of TCM
was distributed to TCM practitioners who had been working in the
field of research for at least 5 years and had published at least one
related scientific article in the last 5 years. Internal consistency test
was performed for all questions to verify the reliability of the
questionnaire. Principal-component analysis was performed for
remaining items after Kaiser-Meyer-Olkin (KMO) index and Bartlett’s
test of sphericity. A linear combination model was then built to
evaluate the contribution of various factors involved for the selection
of TCM into the health care reimbursement or insurance system.
Results: Of 429 questionnaires issued, 137 were returned from
respondents from 31 medical and research institutions, giving asee front matter Copyright & 2013, International
r Inc.
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ersity of Newcastle, Callaghan, NSW 2308, Austrarecovery rate of 31.93%. Internal consistency coefficient obtained
was 0.745, indicating good reliability of this measurement scale, and
the data passed the KMO test and Bartlett’s test of sphericity (KMO
index ¼ 0.691). In addition, eight common factors were extracted
after the rotation of principal-component analysis with a cumula-
tive variance of 70.92%. Conclusions: Our findings suggested that
factors to be considered during the selection of TCM in health care
reimbursement or insurance system include patient preference,
long-term outcomes, comparative study of alternative options
between TCM and allopathic medicine or biomedicine, pharmacoe-
conomic evaluation results and the overall economic burden of
patients, and side effects of TCM. In addition, the TCM experts
stressed the need of cost-effectiveness assessment of the expensive
TCM of similar therapeutic functions during the selection process.
Moreover, during the evaluation of health-related quality of life of
TCM, they warned to avoid overexaggeration of their roles and that
the generic scale should be modified according to the clinical
circumstances.
Keywords: cost-effectiveness, influencing factors, principal-
component analysis, reimbursement, Traditional Chinese Medicine.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Complementary and alternative medicine (CAM) has gained
increasing popularity over the last several decades. The World
Health Organization reported that in some Asian and African
countries, 80% of the population depends on traditional medicine
for its primary health care. Even in many developed countries,
70% to 80% of the population has used some form of alternative
or complementary medicine [1]. The global market for herbal
medicines currently stands at more than US $83 billion annuallyand is growing steadily at a rate of between 3% and 12% per
annum [2]. This is despite the fact that the patients or consumers
have to make out-of-pocket payments, because CAM treatments
often are reimbursable neither by public finance nor by health
insurance.
Such a consumer-driven development has resulted in an
increasing interest in research in CAM. In fact, the World Health
Organization and many other national and local agencies are also
paying more attention to the research of CAM and significant
efforts have been made to validate the efficacy and effectivenessSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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for Complementary and Alternative Medicine in America has
funded more than 2500 research projects, resulting in more than
3300 scientific articles in peer-reviewed journals. This effort has
increased the knowledge base of the effects, efficacy, safety, and
promise of many CAM interventions [4]. The increase in the
importance of CAM internationally was highlighted by the fact
that the US president’s 2011 fiscal year budget included a request
of $132 million for the National Center for Complementary and
Alternative Medicine of the National Institutes of Health, $3.2
million more than the comparable fiscal year 2010 appropriation.
The reason for this increased budget was that NHIS data showed
that Americans spent $33.9 billion out of pocket on CAM,
accounting for approximately 1.5% of total health care expendi-
tures and 11.2% of total out-of-pocket expenditures on health
care. Consequently, with such a sizable outlay spent on CAM, the
government must ensure the protection of public health and
safety, and therefore the increased research funding to enable the
achievement of good professional practice of CAM. Likewise, in
the United Kingdom, there are also many discussions and
research on whether CAM should be included in the National
Health Service or local National Health Service [5–7].
In congruent with the worldwide trend, Traditional Chinese
Medicine (TCM) as a major component in CAM has also been
gaining increasing popularity over the last several decades.
Internationally, some forms of TCM (e.g., acupuncture) have
already been integrated into national health care reimbursement
or insurance systems in many countries. With the increasing
interest of using TCM worldwide, there is increased pressure for
health care agencies to decide whether to include TCM into their
mainstream health care reimbursement or insurance system.
This need of a judgment is leading gradually to increasing cost-
effectiveness and patients’ outcome assessment research of
TCM. In recent years, many studies on economic evaluation
and outcome research on TCM treatments including Qi Gong,
Tai Chi, massage, acupuncture, and so on were published. The
attempts by these studies to elucidate the cost-effectiveness of
TCM and impact of TCM on patients’ reported outcomes, how-
ever, have been largely unsatisfactory, with many ambiguous and
inconclusive results [8,9]. A plausible reason is a lack of attention
to and probably understanding of the theoretical characteristics
of TCM, which are completely different from those of allopathic
medicine or biomedicine. The paucity of evidence to support the
effectiveness of TCM treatments is a dilemma faced by many
health administrators and insurers when making reimbursement
decisions.
This same problem is also encountered in China, and the
pressure is probably much more acute. To build a basic medicine
system to cover the health care need of the population was the
fundamental goal of Chinese new medical reform plan passed by
the Chinese government in November 2009. Emphasizing equal
importance of both TCM and allopathic medicine or biomedicine
in health care delivery and maintenance is one of the basic
principles of the reform plan. This principle is illustrated in the
National List of Essential Drugs (for Primary Healthcare Facilities)
released in 2009. In this list, there are 307 items: 205 Western
medicines (all generic) and 102 TCM products [10]. Although a
substantially reduced list compared with the previous Essential
Drug List of 2004, which covered more than 2000 products (773
Western medicines and 1260 TCM products), the issue of how to
decide the inclusion of a new TCM product still remains. It is
unclear how the culling process was carried out for the new
version of Essential Drug List. Nevertheless, to show its value to
public health, TCM must show its effectiveness in disease
management, prevention, and control. Otherwise, it is difficult
to justify the reimbursement of TCM from public finance through
the health insurance system.There is still a lack of accepted scientific criteria and methods,
however, to assess and select TCM (including traditional thera-
pies and herbal medicine) into the health care insurance system
in China. A major reason is the fuzziness and uncertainty in what
evidence and evaluation standard of clinical efficacy are neces-
sary, and there is no consensus among the TCM practitioners and
experts. Without a more objective assessment of effectiveness, it
is impossible to judge whether the national health resources
spent on TCM are providing the value of money. The criterion of
providing value for money (i.e., cost-effectiveness) has become a
determining factor for public drug reimbursement in many
countries and jurisdictions nowadays. Therefore, it is becoming
even more urgent to adopt some criteria to assess ‘‘value for
money’’ of TCM during the new medical reforms in China today.
At present, there is a paucity of studies on TCM selection into
the health care system in China from the perspective of practi-
tioners (or other stakeholders for that matter), but the national
decision makers attach great importance to the expert advice of
TCM practitioners for the inclusion and reimbursement of TCM.
So, our current study attempted to survey expert TCM practi-
tioners in China to elucidate critical issues when assessing the
effectiveness of TCM, and to ascertain influencing factors of TCM
selection for reimbursement in the public health care system.
This information may be a starting point to provide a scientific
and acceptable standard for the assessment of the effectiveness
of TCM for drug reimbursement decision.Materials and Methods
Selection of Survey Subjects
TCM experts were selected on the basis of personal contact and
scientific publications in related fields of TCM. The inclusion
criteria were that the expert should have been working in the
field for at least 5 years and had published at least one related
research article in the past 5 years. Experts were contacted by
e-mail, mail, or telephone.Design of Survey Questionnaire
After reviewing the available literature, a survey questionnaire
was drafted. To ensure relevance and applicability, the initial
draft of the survey questionnaire was reviewed by three TCM
experts working in Second Affiliated Hospital of Liaoning Uni-
versity of Traditional Chinese Medicine, Institute of Chinese
Medicine of Beijing University of Chinese Medicine, and Chengdu
University of Traditional Chinese Medicine, respectively. The
experts were chosen from the capital, northeastern, and south-
western regions to improve the representativeness. Modifications
were made to the questionnaire on the basis of their feedbacks.
The questions included in the survey questionnaire were fina-
lized after another round of inputs from these experts.
The final questionnaire comprised three main sections (see
Appendix 1 in Supplemental Materials found at http://dx.doi.org/
10.1016/j.vhri.2013.01.004). Section 1 captured personal informa
tion about the expert respondents including gender, age, institu
tion, professional experience, and so on. Section 2 comprised 20
close-ended questions about evaluating the cost-effectiveness
and other influencing factors in the selection of TCM and the
questions were scored according to a seven-point Likert-type
scale ranging from 7 (strongly agree) to 1 (strongly disagree), with
undecided scored at 4 in the middle. Section 3 had two
open-ended questions soliciting any extra opinions from the
respondents.
Table 1 – Institution of respondents.
Location Institution n
Beijing (N ¼ 70) Dongzhimen Hospital of Beijing University of Chinese Medicine 22
Beijing Friendship Hospital 24
PLA General Hospital 4
Guang An Men Hospital, China Academy of Traditional Chinese Medicine 5
People’s Hospital of Peking University 4
Beijing University of Chinese Medicine Centre for Evidence-Based Medicine 1
Eastern Hospital of Beijing Chinese Medicine University 2
Third Affiliated Hospital of Traditional Chinese Medicine of Beijing University 1
Basic Department of Traditional Chinese Medicine of Beijing University 2
Institute of Chinese Medicine of Beijing University of Chinese Medicine 1
Beijing Hospital of Capital Medical University 3
Beijing Ditan Hospital 1
Liaoning (N ¼ 26) First Affiliated Hospital of Liaoning University of Traditional Chinese Medicine 10
Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine 10
Liaoning University of Traditional Chinese Medicine 6
Sichuan (N ¼ 6) Sichuan Academy of Traditional Chinese Medicine 1
Affiliated Hospital of Chengdu University of Traditional Chinese Medicine 1
Chengdu University of Traditional Chinese Medicine 4
Hunan (N ¼ 3) Hunan Academy of Traditional Chinese Medicine 1
Hunan University of Traditional Chinese Medicine 1
Affiliated Hospital of Hunan University of Traditional Chinese Medicine 1
Henan (N ¼ 8) Chinese Medicine Hospital of Henan Province 2
Henan University of Traditional Chinese Medicine 6
Shanghai (N ¼ 7) Shanghai University of Traditional Chinese Medicine 4
Shanghai Changhai Hospital 3
Zhejiang (N ¼ 4) Zhejiang University of Traditional Chinese Medicine 2
Hangzhou Chinese Medicine Hospital 2
Jiangsu (N ¼ 4) China Pharmaceutical University 4
Guangzhou (N ¼ 9) Guangzhou University of Traditional Chinese Medicine 4
First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine 5
Total 137
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Likert-type scale scores obtained from Section 2 were separately
analyzed with questions relating to TCM cost-effectiveness, and
those relating to influencing factors. Cronbach’s alpha test was
performed to test the internal consistency for these question-
naires. The Hotelling’s T-squared test was performed to assess
the data distribution.
Principal-component analysis (PCA) was performed for
remaining items after Kaiser-Meyer-Olkin index and Bartlett’s
test of sphericity. All data were analyzed by using SPSS 17.0 (SPSS,
Inc., Chicago, IL). Qualitative analysis was performed for the
open-ended questions in Section 3.Table 2 – Age distribution of respondents.
Years n (%)
30–39 24 (17.5)
40–49 19 (13.89)
50–59 58 (42.33)
60–69 27 (19.71)
70–79 8 (5.84)
480 1 (0.73)
Mean  SD 53.10  12.51Results
Expert Panel
Of 429 questionnaires issued, 66 recipients (15.48%) responded
initially. A follow-up e-mail and telephone calls resulted in an
extra 76 responses. Of these, five questionnaires were excluded
because of missing information. The final 137 eligible question-
naires were returned by respondents from 31 medical and
research institutions in nine provinces and cities in China, giving
a response rate of 31.93%. The characteristics of the respondents
are detailed as per Tables 1 to 3.
A breakdown of the source of the 137 questionnaires showed
that the respondents were from cities and provinces scattered
around China, with the majority of the respondents from Beijing
(70) and Liaoning (26). Most of these expert respondents workedin medical institutions, and some were engaged in teaching and
research in universities.
Most respondents (62.04%) were in the 50- to 69-year-old age
bracket, with nine senior experts older than 70 years participat-
ing in our survey.
When coming to practicing experience, the respondents had
practices that covered nearly every aspect of TCM practice in
China (Table 3).
Statistical Analysis
For internal consistency coefficient of reliability of the 20 Likert-
type items in Section 2, internal consistency coefficients obtained
was 0.745, indicating good reliability of this measurement scale.
The items were also examined by using Kaiser-Meyer-Olkin
index and Bartlett’s test of sphericity. The Kaiser-Meyer-Olkin
index of section 2 was 0.691, which was above 0.5. In addition, the
probability of Bartlett test sphere and the significance of statistics
was 0.000, indicating that the use of PCA was appropriate. This
Table 3 – Professional experience of experts.
Professional category n
Massage Department of Chinese Medicine 6
Internal Chinese Medicine 10
Acupuncture and Gynecology of Chinese Medicine 8
Gynecology of Chinese Medicine 4
Oncology of Chinese Medicine 6
Endocrinology of Chinese Medicine 5
Neurology of Chinese Medicine 4
Cardiology of Chinese Medicine 6
General Surgery of Chinese Medicine 9
Ophthalmology of Chinese Medicine 5
Rheumatology of Chinese Medicine 6
Emergency Chinese Medicine 5
Integrated Traditional and Western Medicine 7
Cosmetology of Chinese Medicine 7
Gastroenterology of Chinese Medicine 5
Infectious Diseases of Chinese Medicine 3
Dermatology of Chinese Medicine 5
Stomach Division of Chinese Medicine 5
Clinical Traditional Chinese Medicine 11
Nephrology of Traditional Chinese Medicine 4
Encephalopathy of Chinese Medicine 3
Osteoarthritis of Chinese Medicine 4
Public Relations of Chinese Medicine 9
Total 137
Table 4 – Results of principal-component analy-
sis—total variance explained.
Component Initial Eigenvalues
Total % of variance Cumulative %
1 4.169 20.846 20.846
2 2.348 11.739 32.584
3 1.960 9.802 42.386
4 1.406 7.031 49.417
5 1.326 6.628 56.045
6 1.086 5.429 61.473
7 1.004 5.021 66.494
8 0.886 4.429 70.923
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distribution.
Hereafter, principal-component V PCA was used to extract
common factors in these questionnaires. After the extraction of
common factors, all communalities were over 0.5, indicating that
more than 50% of the variation in the variables can be explained
by these common factors.
The load value of each common factor was obtained through
the maximum variance of orthogonal rotation matrix. As shown
by the Scree Plot, eight common factors were extracted (Fig. 1),
with a cumulative variance of 70.92% (Table 4).
The eight major factors identified were the effectiveness of
TCM treatment for incurable diseases and long-term treatment of
chronic diseases, clinical acceptance among the TCM practi-
tioners, availability of alternatives, cost-effectiveness evaluation
of TCM, treatment impact of TCM on health-related quality of life
(HR-QOL), holistic treatment effect, overall economic burden of
TCM treatment to patients, and side effects of TCM. These factors
are labeled as components 1 to 8, respectively, in Table 4. The
relationship between these factors and the questions in the
questionnaire is detailed in Appendix 2 in Supplemental Materi-
als found at http://dx.doi.org/10.1016/j.vhri.2013.01.004.
According to the component matrix and its corresponding
Eigenvalue, we calculated the unit Eigenvectors for principal
component linear combination model (please refer to Appendix
3 for the process and results of model construction in Supple-
mental Materials found at http://dx.doi.org/10.1016/j.vhri.2013.01.
004).Response to Open-Ended Questions
As previously mentioned, the two open-ended questions in this
section solicited opinions from the experts about factors to be
considered when deciding on the inclusion of TCM into basic
medical insurance directory and Essential Drugs List, and other
issues relating to the HR-QOL measurement process for treat-
ment with TCM.Among the 137 returned questionnaires, 27 and 23 did not
contain answers for the first and second questions, respectively.
From those who answered these questions, most experts
stressed the need to focus on cost-effectiveness assessment of
the expensive medicine that already has alternative products
treating similar conditions. For the evaluation HR-QOL during
TCM treatment, they cautioned about the overexaggeration of
their roles and advocated the modification of the existing generic
scale for TCM use according to the clinical circumstances.Discussion
This study is the first attempt for exploring the criteria for
consideration of TCM selection into health care reimbursement
and insurance system in China. The information obtained from
our study reveals what the TCM practitioners view as important
factors in assessing the efficacy of TCM treatment. Besides being
important for the health care decision makers in China during
the selection of TCM drugs for inclusion into the Essential Drug
List and insurance plan, the information would also provide
a framework for other jurisdictions when considering whether
to reimburse TCM from public finance or private health
insurance plan.
In this current study, we have extracted information from the
responses of expert TCM practitioners from various parts of
China about factors that they considered important in selecting
TCM for health insurance plan or Essential Drug List inclusion.
We shall examine the factors identified and evaluate the ratio-
nale for their selection by the TCM experts.
From the results of our survey, during the selection of TCM
into health care reimbursement or insurance system, the first
factor to consider is the long-term outcomes with TCM treatment
of incurable and chronic diseases. In other words, the TCM
experts advocate focusing on the advantages of TCM in compar-
ison to those of biomedicine particularly in the treatment of
incurable and chronic diseases. For example, Qixing Huatuozai-
zao pill is included in the Medical Insurance Directory of several
countries including Russia and Vietnam because of its unique
efficacy for treating cardiovascular diseases.
The second factor is clinical acceptance among TCM practi-
tioners, and this really represents the degree of acceptance and
the extent of experience of using the particular TCM product in
managing the condition, and this really does not differ from the
evaluation of conventional pharmaceutical drugs.
The third factor is the availability of clinical alternatives. This
factor has been applied in the selection of drug inclusion in the
Chinese Essential Drug List. For example, two-thirds of TCM
varieties from the 2004 Essential Drug List were excluded in the
new Chinese Essential Drug List in 2009 because of existing
alternative varieties of similar products.
Fig. 1 – Scree Plot Eigenvalues.
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effectiveness and price of the TCM product. With the increased
emphasis on efficiency under the current situation of resource
constraints and increased demands for health care, TCM, as
indeed do all other treatments, should be required to undergo
rigorous cost-effectiveness evaluation before reimbursement
decision.
The fifth factor is the treatment impact of TCM on HR-QOL.
This is logical because patient preference or HR-QOL has become
the second standard for formulary decisions in many published
pharmacoeconomic guidelines, and theoretically congruent with
the holistic disease management concept of TCM.
The sixth factor is holistic treatment effect, which is the
improvement in essence, spirit, and energy of patients. Like HR-
QOL, it is reasonable to suggest this factor because the concep-
tion and philosophy of TCM treatment is completely different
from that of allopathic medicine. For instance, ‘‘Co-existing with
the tumor’’ has been advocated in the TCM treatment of cancer,
and the concept is the recuperation of patients’ essence, spirit,
and energy to allow the patient to control the tumor, rather than
directly make the tumor shrink or disappear.
The seventh factor is the overall economic burden including
all health resources consumption in the diagnosis and treatment
of the disease by using TCM. By considering beyond just the price
of drugs, this highlights that the TCM practitioners in China are
conscious that TCM treatments may not be cheaper than allo-
pathic medicine.
The eighth factor is about the safety of TCM. Although TCM has
been perceived to produce much lesser toxic side effects than do
allopathic medicine by the general public, in fact, a large number of
cases of toxicity caused by TCM products have been reported in
China. The ‘‘Aristolochic Acid Warning’’ issued by the World Health
Organization also shows the complexity of TCM side effects [11],
and the safety of TCM products should be treated with the same
seriousness as are drugs used in allopathic medicine.
Intuitively, because of different philosophical foundations
between TCM (which aims at the holistic adjustment of the body
system including the improvement in physical and mental con-
ditioning of the subject) and biomedicine (which is deductive and
focus on individual symptoms), we would expect the factors
identified to be quite different. Rather surprisingly, however, our
results showed that the outcome indicators considered important
for the assessment of the efficacy or the selection of TCM by TCM
practitioners in China have many commonality with biomedicine.A possible explanation may be the close cooperation in patient
management between TCM practitioners and practitioners of allo-
pathic medicine in China, and their mutual influences.
Another reason may be that even with their theoretical differ-
ence, there is a convergence in the desire to achieve the best
outcomes for the patients, and the best outcomes would be similar
whether the patient is treated with TCM or with allopathic
medicine. Nevertheless, our results show that some differences
still remain and would need further exploration. The major differ-
ence really concerns the fundamental philosophical difference
between TCM and allopathic medicine in assessing and prioritizing
outcomes [12]. To resolve this difference (if at all necessary or
feasible) will require much better interactions between practitioners
and researchers of TCM and allopathic medicine [13].
Despite our best efforts, our study does contain some limita-
tions. First, we focused on the opinions of clinical TCM experts
and did not capture the opinion from medical decision makers or
other stakeholders. This, however, does not distract that the
information obtained would provide a framework for soliciting
opinions from other stakeholders in future studies. Furthermore,
most participating experts were from large medical and scientific
research institutions, and we did not solicit any TCM practi-
tioners’ advice of small hospitals or community health care
institutions. As a result, we cannot exclude the possibility of a
selection bias and its potential effect on the results. Nevertheless,
from the geographic distribution, year, and area of practice of the
respondents, we would be reasonably confident that our partici-
pants would be representative of TCM practitioners in China.
In addition, in our current study, we have built a model to
assess the relative weightage of these factors in the clinical
decision for selecting TCM into the Essential Drug List or health
reimbursement system. Further efforts, however, will be neces-
sary to validate and improve the model built from our present
study through specific empirical research before its application in
TCM drug selection process for reimbursement purpose.
Finally, an additional limitation is that the cumulative var-
iance of eight common factors extracting through PCA was only
70.92%, not over 85%. This may be related to the lack of
familiarity of some expert respondents about cost-effectiveness
assessment or essential medicine system.
In conclusion, despite these limitations, our results would
provide a preliminary framework for future study on the criteria
for assessing TCM products in China as well as for other
jurisdictions.
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